/Companies

INVO Bioscience

NASDAQ: IVF

Sarasota, US · Nevada corporation · 1 known investors

Find your way into INVO Bioscience

Sign up to see every warm intro you have to INVO Bioscience

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the INVO Bioscience team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

INVO Bioscience operates fertility clinics and develops fertility-related medical devices and technologies. The company acquires and operates U.S.-based fertility clinics that provide in vitro fertilization, intravaginal culture procedures using its INVOcell device, and related assisted reproductive services, while also licensing its INVOcell technology to third-party clinics.

Founders & leadership

MC
Michael CampbellChief Operating Officer and VP of Business Development
AGAndrea Goren
Andrea GorenChief Financial OfficerAndrea Goren is Chief Financial Officer of INVO Bioscience, which operates fertility clinics and develops fertility medical devices and technologies. She has over 20 years of experience in private equity, investment banking, and corporate finance, including founding two investment funds, serving as CFO of a publicly traded company, and holding board positions at private and public companies.
SS
Steven ShumChief Executive Officer

Board

TD
Trent DavisBoard director
MS
Matthew SzotBoard director
BR
Barbara RyanBoard director
RM
Rebecca MessinaBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$7.3M disclosed across 5 of 6 rounds · 2018–2024

▶$3MraisedApr 2023 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael CampbellExecutive Officer
  • Andrea GorenExecutive Officer
  • Trent DavisDirector
  • Steven ShumExecutive Officer, Director
  • Matthew SzotDirector
  • Barbara RyanDirector
  • Rebecca MessinaDirector
Offering amount
$3M
Amount sold
$3M
Sales commissions
$148.8K
Proceeds to insiders
$130K
Placement agents
MAXIM GROUP LLC
First sale
Mar 2023
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedMar 2023 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Rebecca MessinaDirector
  • Steven ShumExecutive Officer, Director
  • Andrea GorenExecutive Officer
  • Barbara RyanDirector
  • Jeffrey SegalDirector
  • Trent DavisDirector
  • Michael CampbellExecutive Officer
  • Matthew SzotDirector
Offering amount
$500K
Amount sold
$500K
Sales commissions
$36K
Proceeds to insiders
$10K
Placement agents
Carter, Terry & Company, Inc.
First sale
Feb 2023
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$275KraisedJan 2023 · 7 investors · Other Health Care
Rule 506(c)
Officers, directors & promoters on the filing
  • Andrea GorenExecutive Officer
  • Barbara RyanDirector
  • Jeffrey SegalDirector
  • Rebecca MessinaDirector
  • Steven ShumExecutive Officer, Director
  • Trent DavisDirector
  • Michael CampbellExecutive Officer
  • Matthew SzotDirector
Offering amount
$3.5M
Amount sold
$275K
Proceeds to insiders
$10K
First sale
Jan 2023
Incorporated
Corporation, Nevada
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$3.5MraisedJul 2020 · 22 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Trent DavisDirector
  • Steven ShumExecutive Officer, Director
  • Debra HoopesExecutive Officer
  • Kevin DoodyDirector
  • Kathleen T. KarloffDirector
  • Michael J. CampbellExecutive Officer, Director
Offering amount
$3.5M
Amount sold
$3.5M
Minimum investment
$25K
Sales commissions
$236K
Placement agents
Roth Capital, LLC, Tribal Capital Markets LLC
First sale
May 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15KraisedJan 2018 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven T ShumDirector
  • Michael J. CampbellDirector
  • Robert J BowdringDirector
  • Kevin DoodyDirector
  • Kathleen T KarloffExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$15K
Minimum investment
$5K
Proceeds to insiders
$80K
First sale
Jan 2018
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$3.1Mvaluation at IPOJan 2025 · $0.70/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does INVO Bioscience do?
INVO Bioscience operates fertility clinics and develops fertility-related medical devices and technologies. The company acquires and operates U.S.-based fertility clinics that provide in vitro fertilization, intravaginal culture procedures using its INVOcell device, and related assisted reproductive services, while also licensing its INVOcell technology to third-party clinics.
Who are INVO Bioscience's investors?
INVO Bioscience's investors include FOD Capital.
How much funding has INVO Bioscience raised?
INVO Bioscience has disclosed $7.3M raised across 5 of its 6 known rounds.
Where is INVO Bioscience headquartered?
INVO Bioscience is headquartered in Sarasota, US.